Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics (GB:0VRQ)
:0VRQ
RESEARCH TOOLSreports
0VRQ Analyst Ratings
Moderate Buy
12 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0VRQ Stock 12 Month Forecast
Average Price Target
$67.47
▲(76.02% Upside)
| Highest Price Target$105.00 | Average Price Target$67.47 | Lowest Price Target$35.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$79
Buy
106.10%
Upside
Reiterated
05/16/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$79
Buy
106.10%
Upside
Reiterated
05/16/25
Best Analysts Covering Crispr Therapeutics AG
Which Analyst Should I Follow If I Want to Buy GB:0VRQ and Sell After:
1 Month
xxx
Success Rate
12/18 ratings generated profit
Average Return
+9.43%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.43% per trade.
3 Months
xxx
Success Rate
23/41 ratings generated profit
Average Return
+12.30%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.10% of your transactions generating a profit, with an average return of +12.30% per trade.
1 Year
Success Rate
18/41 ratings generated profit
Average Return
+16.87%
reiterated a buy rating 14 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 43.90% of your transactions generating a profit, with an average return of +16.87% per trade.
2 Years
xxx
Success Rate
14/41 ratings generated profit
Average Return
+1.48%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 34.15% of your transactions generating a profit, with an average return of +1.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0VRQ Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
11
18
16
18
16
Buy
9
5
4
2
3
Hold
9
9
7
8
6
Sell
3
2
2
1
0
Strong Sell
0
0
0
0
0
total
32
34
29
29
25
Each month's total comprises the sum of three months' worth of ratings.
0VRQ Financial Forecast
0VRQ Stock Forecast FAQ
What is GB:0VRQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics’s 12-month average price target is 67.47.
What is GB:0VRQ’s upside potential, based on the analysts’ average price target?
Crispr Therapeutics has 76.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Crispr Therapeutics a Buy, Sell or Hold?
Crispr Therapeutics has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 5 hold ratings and 0 sell ratings.
What is Crispr Therapeutics’s share price target?
The average share price target for Crispr Therapeutics is 67.47. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $105.00 ,and the lowest forecast is $35.00. The average share price target represents 76.02% Increase from the current price of $38.33.
The highest analyst share price target is $105.00 ,and the lowest forecast is $35.00. The average share price target represents 76.02% Increase from the current price of $38.33.
What do analysts say about Crispr Therapeutics?
Crispr Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of Crispr Therapeutics?
To buy shares of GB:0VRQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.